A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481 - PubMed (original) (raw)
Clinical Trial
. 2006 Jun 15;107(12):4606-13.
doi: 10.1182/blood-2005-06-2448. Epub 2006 Feb 9.
Affiliations
- PMID: 16469874
- DOI: 10.1182/blood-2005-06-2448
Free article
Clinical Trial
A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481
Gita V Massey et al. Blood. 2006.
Free article
Abstract
A unique transient leukemia (TL) has been described in newborns with Down syndrome (DS; or trisomy 21 mosaics). This leukemia has a high incidence of spontaneous remission; however, early death and subsequent development of acute megakaryoblastic leukemia (AMKL) have been reported. We prospectively evaluated 48 infants with DS and TL to determine the natural history and biologic characteristics of this disease, identify the clinical characteristics associated with early death or subsequent leukemia, and assess the incidence of subsequent leukemia. Blast cells associated with TL in DS infants exhibited FAB M(7) morphology and phenotype. Most infants (74%) had trisomy 21 (or mosaicism) as the only cytogenetic abnormality in the blast cells. Most children were able to spontaneously clear peripheral blasts (89%), normalize blood counts (74%), and maintain a complete remission (64%). Early death occurred in 17% of infants and was significantly correlated with higher white blood cell count at diagnosis (P < .001), increased bilirubin and liver enzymes (P < .005), and a failure to normalize the blood count (P = .001). Recurrence of leukemia occurred in 19% of infants at a mean of 20 months. Development of leukemia was significantly correlated with karyotypic abnormalities in addition to trisomy 21 (P = .037). Ongoing collaborative clinical studies are needed to determine the optimal role of chemotherapy for infants at risk for increased mortality or disease recurrence and to further the knowledge of the unique biologic features of this TL.
Comment in
- Use of the International System for Human Cytogenetic Nomenclature (ISCN).
Gonzalez Garcia JR, Meza-Espinoza JP. Gonzalez Garcia JR, et al. Blood. 2006 Dec 1;108(12):3952-3; author reply 3953. doi: 10.1182/blood-2006-06-031351. Blood. 2006. PMID: 17114573 No abstract available.
Similar articles
- Use of the International System for Human Cytogenetic Nomenclature (ISCN).
Gonzalez Garcia JR, Meza-Espinoza JP. Gonzalez Garcia JR, et al. Blood. 2006 Dec 1;108(12):3952-3; author reply 3953. doi: 10.1182/blood-2006-06-031351. Blood. 2006. PMID: 17114573 No abstract available. - Transient leukemia in newborns with Down syndrome.
Massey GV. Massey GV. Pediatr Blood Cancer. 2005 Jan;44(1):29-32. doi: 10.1002/pbc.20141. Pediatr Blood Cancer. 2005. PMID: 15558701 Review. - [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D, Reinhardt K, Neuhoff C, Sander A, Klusmann JH, Pekrun A, Sauerbrey A, von Stackelberg A, Rössig C, Creutzig U, Kolenova A. Reinhardt D, et al. Klin Padiatr. 2012 Apr;224(3):153-5. doi: 10.1055/s-0032-1308988. Epub 2012 Apr 18. Klin Padiatr. 2012. PMID: 22513796 German. - Telomerase and the benign and malignant megakaryoblastic leukemias of Down syndrome.
Holt SE, Brown EJ, Zipursky A. Holt SE, et al. J Pediatr Hematol Oncol. 2002 Jan;24(1):14-7. doi: 10.1097/00043426-200201000-00005. J Pediatr Hematol Oncol. 2002. PMID: 11902731 - Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome.
Brink DS. Brink DS. Adv Anat Pathol. 2006 Sep;13(5):256-62. doi: 10.1097/01.pap.0000213039.93328.44. Adv Anat Pathol. 2006. PMID: 16998319 Review.
Cited by
- Four Cases of Myeloproliferative Disorders Associated With Down Syndrome: Distinguishing ML-DS From TAM-DS: Distinguishing TAM-DS and ML-DS: Report of 4 Cases.
Boumeghar K, Daliphard S, Buchbinder N, Boutet C, Penther D, Etancelin P, Bourgain J, Buchonnet G, Bera E, Bobée V. Boumeghar K, et al. Case Rep Hematol. 2024 Oct 23;2024:9962512. doi: 10.1155/2024/9962512. eCollection 2024. Case Rep Hematol. 2024. PMID: 39479474 Free PMC article. - Down syndrome-associated leukaemias: current evidence and challenges.
Mason NR, Cahill H, Diamond Y, McCleary K, Kotecha RS, Marshall GM, Mateos MK. Mason NR, et al. Ther Adv Hematol. 2024 Jul 23;15:20406207241257901. doi: 10.1177/20406207241257901. eCollection 2024. Ther Adv Hematol. 2024. PMID: 39050114 Free PMC article. Review. - GATA1 in Normal and Pathologic Megakaryopoiesis and Platelet Development.
Takasaki K, Chou ST. Takasaki K, et al. Adv Exp Med Biol. 2024;1459:261-287. doi: 10.1007/978-3-031-62731-6_12. Adv Exp Med Biol. 2024. PMID: 39017848 Review. - Cytokine profiling in 128 patients with transient abnormal myelopoiesis: a report from the JPLSG TAM-10 trial.
Yamato G, Tsumura Y, Muramatsu H, Shimada A, Imaizumi T, Tsukagoshi H, Kaburagi T, Shiba N, Yamada Y, Deguchi T, Kawai T, Terui K, Ito E, Watanabe K, Hayashi Y. Yamato G, et al. Blood Adv. 2024 Jun 25;8(12):3120-3129. doi: 10.1182/bloodadvances.2023011628. Blood Adv. 2024. PMID: 38691583 Free PMC article. Clinical Trial. - Transient Abnormal Myelopoiesis: An Abnormal Course and the Efficacy of Delayed Treatment.
Mishra P, Fajrudheen M, Sahoo T, Som TK, Biswal S, Chhabra G. Mishra P, et al. Cureus. 2024 Feb 14;16(2):e54219. doi: 10.7759/cureus.54219. eCollection 2024 Feb. Cureus. 2024. PMID: 38496060 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials